The Crohn's & Colitis Foundation collaborates with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below, and the Crohn's & Colitis Foundation does not endorse any particular study.
For a comprehensive listing of all research studies currently recruiting, please visit our IBD Clinical Trial Finder.
The purpose of the study is to evaluate the safety and effectiveness of the study medicine in adults with ulcerative colitis.
Primary objective: To compare clinical efficacy by evaluating the clinical response to CBP-307 (P.O. for 12 consecutive weeks) versus placebo in subjects with moderate to severe UC
Primary Objective: To Evaluate the Effect of GB004 Compared to Placebo on Clinical Remission
The purpose of the LATTICE-UC is to evaluate how well the oral investigational drug (called BMS- 986165) works and how safe it is for patients with moderately to severely active ulcerative colitis.
The purpose of the LATTICE-CD is to evaluate how well an oral investigational drug (called BMS- 986165) works and how safe it is for patients with moderately to severely active Crohn’s disease.
To assess the change in symptoms and overall safety of TD-1473, which is an investigational product, in moderately-to-severely active Crohn's disease.
- To evaluate the efficacy of PF-06480605 in induction of clinical remission at Week 14 in participants with moderate to severe active UC.
- To evaluate the safety and tolerability of PF-06480605 during the chronic therapy period (from Week 14 to the End of Study Visit) in participants with moderate to severe active UC during the chronic therapy period.
The VEGA study is evaluating the safety and effectiveness of the study medicine in adults with ulcerative colitis (UC).
To demonstrate the efficacy of SER-287, after 10 weeks of induction dosing (following vancomycin pre-treatment), in achieving clinical remission.
Full Study Title: A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled (Entyvio), Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of A Study Drug in Participants with Moderately to Severely Active Ulcerative Colitis [Expedition]
The primary objective of this study is to evaluate the efficacy and safety of a study drug versus placebo in patients with moderately to severely active Ulcerative Colitis.